Tvardi Therapeutics, Inc.
TVRD
Rank in Stocks
#27419
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages... Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Share Price
$1.18
Last synced: 2026-11-13
Market Cap
$14.93M
Change (1 day)
1.72%
Change (1 year)
-70.72%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tvardi Therapeutics, Inc. (TVRD)
Category
Healthcare
EPS for Tvardi Therapeutics, Inc. (TVRD)
EPS as of September 2026 TTM: $-2.68
According to Tvardi Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-2.68. At the end of 2025 the company had an EPS of $-2.46, an increase over its 2024 EPS of $-46.59.
EPS history for Tvardi Therapeutics, Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.68 | 8.94% |
| 2025 | $-2.46 | -94.72% |
| 2024 | $-46.59 | 2,418.38% |
| 2023 | $-1.85 | -15.91% |
| 2022 | $-2.20 | -96.50% |
| 2021 | $-62.77 | -1,082.32% |
| 2020 | $6.39 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -66.79% |
US
|
|
| $15.66 | -684.33% |
US
|
|
| $-7.07 | 163.81% |
US
|
|
| $-5.29 | 97.39% |
AU
|
|
| $12.73 | -575.08% |
BE
|
Questions about Tvardi Therapeutics, Inc.'s earnings per share (EPS)
What is Tvardi Therapeutics, Inc.'s earnings per share (EPS)?
Tvardi Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-2.68, as of Sep 2026.
What was Tvardi Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tvardi Therapeutics, Inc.'s earnings per share (EPS) was $-2.46, compared with $-46.59 in 2024.
How has Tvardi Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tvardi Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($6.39) and lowest in 2021 ($-62.77).
How does Tvardi Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Tvardi Therapeutics, Inc.'s earnings per share (EPS) ($-2.68) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.